We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Product recall for L(A)B Cryo Fat Loss Belt presenting a risk of electric shock.
Healthcare professionals are reminded to inform patients about the common and serious side effects associated with glucagon-like peptide-1 receptor agonists (GLP-1RAs).
Safety leaflet on topical corticosteroids and withdrawal reactions to help patients and their carers to use these medicines safely.
The Medicines and Healthcare products Regulatory Agency (MHRA) is reminding healthcare professionals to ensure patients are aware of the known side effects of glucagon-like peptide-1 (GLP-1) receptor agonists.
Outlines the provisions of the Food (Promotion and Placement) (England) Regulations 2021, and provides assistance in understanding and applying them.
Semaglutide is the first weight loss drug approved in the UK as a preventative treatment for those with established cardiovascular disease
Competent authorities of exporting countries should use the relevant model health certificate as a template to create a version exporters can apply for to export fats to Great Britain, the Channel Islands or Isle of Man.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).